ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Simon D. Eiref
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eiref, S. D.
Right arrow Articles by Rosengard, BruceR.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eiref, S. D.
Right arrow Articles by Rosengard, BruceR.

Ann Thorac Surg 1997;64:628-633
© 1997 The Society of Thoracic Surgeons

Original Article: Cardiovascular

Creation of Chimeric Hearts: A Tool for Testing the "Passenger Leukocyte" Hypothesis

Simon D. Eiref, BA, Wei Zhang, MD, Sicco H. Popma, BS, Lisa J. Shah, Jonni S. Moore, PhD, BruceR. Rosengard, MD

Division of Cardiothoracic Surgery, University of Pennsylvania Health System, Philadelphia, Pennsylvania

Background. Bone marrow-derived antigen-presenting cells (APCs) are thought to be a migratory component of organ allografts that activate the rejection response, and recently they have been postulated to play a critical role in tolerance induction. Our goal was to create chimeric hearts (organs with parenchyma and APCs of differing genotype) for use in models of transplantation to test the "passenger leukocyte" theory.

Methods. Murine bone marrow transplantations were performed in two fully major histocompatibility complex (MHC) mismatched strain combinations: C3H -> B10 and CBA -> BALB/c. Recipients were lethally irradiated (10 Gy) and then received 1 x 107 bone marrow cells intravenously. Bone marrow transplant survivors had their organ APCs isolated by digestion with collagenase D, followed by density gradient centrifugation. The APC-enriched fraction was stained with fluorescein-labeled monoclonal antibodies specific for either donor (I-Ak) or recipient (I-Ab/d) class II MHC antigens, which are expressed by all APCs but not by parenchymal cells. Donor and recipient class II expression was determined by flow cytometry.

Results. Sixty-nine of 100 (69.0%) of C3H -> B10 and 52/107 (48.6%) of CBA -> BALB/c bone marrow transplant recipients survived more than 100 days, whereas all B10 (n = 12) and BALB/c (n = 10) irradiation controls died within 14 days. Mortality appeared to be caused by engraftment failure as most recipients died before day 20. Flow cytometry demonstrated complete APC replacement in hearts (n = 17) and spleens (n = 40), as APC-enriched fractions stained only for donor class II MHC antigens.

Conclusion. Bone marrow transplantation leads to replacement of heart APCs in two murine models. Chimeric hearts are now being used to test the role of APCs in allograft rejection and in tolerance induction.




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
W. Y. Szeto, A. M. Krasinskas, D. Kreisel, S. H. Popma, and B. R. Rosengard
Donor antigen-presenting cells are important in the development of obliterative airway disease
J. Thorac. Cardiovasc. Surg., December 1, 2000; 120(6): 1070 - 1077.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 by The Society of Thoracic Surgeons.